NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -81.9% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | 76.6% | 93% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -30,170.1% | -4,859.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -34,745.5% | -5,461.3% |
| EPS Diluted | -1.54 | -5.38 | -1.25 | -1.08 |
| % Growth | 71.4% | -330.4% | -15.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |